(Q35052813)

6 August 2017

1 reference

title

Mycophenolate mofetil: new applications for this immunosuppressant (English)

1 reference

6 August 2017

1 reference

Kevin G Moder

1

1 reference

6 August 2017

publication date

1 January 2003

1 reference

Annals of Allergy, Asthma & Immunology

6 August 2017

published in

1 reference

6 August 2017

volume

90

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

15-19; quiz 20, 78

1 reference

Mycophenolate mofetil: suggested guidelines for use in kidney transplantation

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: A retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Mycophenolate Mofetil Ameliorates Perivascular T Lymphocyte Inflammation and Reduces the Double-Negative T Cell Population in SLE-Prone MRLlpr/lpr Mice

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

The evidence base for the treatment of lupus nephritis in the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Treatment of lupus nephritis--a work in progress

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Mycophenolate mofetil for dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Mycophenolate mofetil in autoimmune and inflammatory skin disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963607-1

7 January 2021

10.1016/S1081-1206(10)63607-1

Identifiers

DOI

1 reference

6 August 2017

1 reference